Science Translational Medicine Publishes First-in-Human Clinical Data and Supporting Preclinical Data for SYNB1020, Synlogic’s Synthetic Biotic™ Medicine in Development as a Potential Treatment for Hyperammonemia

Synlogic Progresses Clinical and Preclinical Pipeline and Outlines 2019 Catalysts

Synlogic Expands Capabilities in Manufacturing with the Appointment of Head of Technical Operations and Establishment of In-house Production of Clinical Trial Material for its Synthetic BioticTM Medicines

Synlogic to Webcast Presentation at the 30th Annual Piper Jaffray Healthcare Conference

Synlogic Reports Third Quarter 2018 Financial Results and Provides Program Updates

Synlogic Presents Data at the 2018 Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD)

Synlogic Announces Third Quarter 2018 Conference Call and Webcast

Synlogic Presents Preclinical Data from First Synthetic BioticTM Clinical Candidate in Immuno-Oncology at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting

Synlogic to Host Analyst & Investor Event at the Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting

Synlogic Appoints Dr. Aoife Brennan as President and Chief Executive Officer

Synlogic to Webcast Presentation at the Leerink Partners Roundtable Series: Rare Disease & Oncology

Synlogic Reports Positive Interim Phase 1/2a Data Demonstrating Safety, Tolerability and Proof-of-Mechanism in Healthy Volunteers for SYNB1618, in Development for the Management of Phenylketonuria (PKU)